|
|
| | NAMPT inhibitor-linker 2 Basic information |
| Product Name: | NAMPT inhibitor-linker 2 | | Synonyms: | NAMPT inhibitor-linker 2;Benzamide, 4-[4-[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]-1-piperazinyl]-N-[[2-fluoro-4-[[[(1S,2S)-2-(3-pyridinyl)cyclopropyl]carbonyl]amino]phenyl]methyl]- | | CAS: | 2241014-82-2 | | MF: | C34H33FN6O5 | | MW: | 624.66 | | EINECS: | | | Product Categories: | | | Mol File: | 2241014-82-2.mol |  |
| | NAMPT inhibitor-linker 2 Chemical Properties |
| Boiling point | 940.2±65.0 °C(Predicted) | | density | 1.395±0.06 g/cm3(Predicted) | | pka | 13.91±0.70(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | NAMPT inhibitor-linker 2 Usage And Synthesis |
| Uses | NAMPT inhibitor-linker 2 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC50s of <7 pM and 40 pM, respectively. | | in vivo | ADC-4 (20 mg/kg, i.v. for 28 days) is tolerated, and causes tumor stasis in mice bearing GIST-T1 cells[1]. | Animal Model: | Female scid-beige (SCID bg) mice[1] | | Dosage: | 20 mg/kg | | Administration: | A single intravenous injection (i.v.) for 28 days | | Result: | Significantly inhibited the growth of tumor in mice. |
| | IC 50 | Traditional Cytotoxic Agents | | References | [1] Karpov AS, et al. Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody-Drug Conjugates. ACS Med Chem Lett. 2018 Jun 28;9(8):838-842. DOI:10.1021/acsmedchemlett.8b00254 |
| | NAMPT inhibitor-linker 2 Preparation Products And Raw materials |
|
|
Tag:NAMPT inhibitor-linker 2(2241014-82-2)
Related Product Information
|
|
Glycinamide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]-
CL2A-SN-38
L-Ornithinamide, N6-[39-[bis(1-deoxy-D-glucitol-1-yl)amino]-1-oxo-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxanonatriacont-1-yl]-N2-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-lysyl-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-1...
PSMA-617
VcMMAE
Val-Cit-PAB-MMAE
|